QRG Capital Management Inc. Decreases Stock Holdings in Hims & Hers Health, Inc. $HIMS

QRG Capital Management Inc. reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 92.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,840 shares of the company’s stock after selling 166,996 shares during the period. QRG Capital Management Inc.’s holdings in Hims & Hers Health were worth $785,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $26,000. Quent Capital LLC purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the 2nd quarter worth $29,000. Bessemer Group Inc. grew its stake in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter valued at about $30,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on HIMS. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, January 5th. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. KeyCorp initiated coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Finally, Zacks Research lowered shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $44.54.

Insiders Place Their Bets

In related news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares in the company, valued at approximately $78,045.46. This represents a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 134,611 shares of company stock worth $4,895,914. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $28.83 on Thursday. The company has a 50 day simple moving average of $35.20 and a two-hundred day simple moving average of $45.31. The stock has a market cap of $6.56 billion, a price-to-earnings ratio of 53.39, a PEG ratio of 5.16 and a beta of 2.37. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a 12 month low of $23.97 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period last year, the business earned $0.32 EPS. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has authorized a stock buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.